fbpx

IPS cells in the treatment of osteoarthritis

In 2012, a British John Gerdon and a Japanese Sinya Yamanaka received the Nobel Prize in Medicine and Physiology for discovering a method for reprogramming adult cells into IPS cells.

IPS cells (induced pluripotent stem cells) are cells with induced pluripotency from which any adult cell can be obtained. Thus, IPS cells have opened up new perspectives in the treatment of many diseases caused by pathological changes in organs, and in bioengineering (growing) tissues in the laboratory.

It has been shown that umbilical cord blood stem cells can serve as optimal  biological material for obtaining IPS cells.

The widespread introduction of IPS cells into clinical practice has been preceded by years of research, primarily on their genetic stability.

And so, according to Bioinformant, one of the Australian biotechnology companies is preparing for the 3rd phase of a clinical trial in which the drug CYP 004, containing mesenchymal stem cells derived from IPS cells, will be used in the treatment of osteoarthritis. It is planned to treat 440 patients with the new method.

The clinical trial will be conducted by the University of Sydney and funded by the Australian Government National Health and Medical Research Council (NHMRC).

In Ukraine, specialists from the Institute of Cell Therapy have also developed an innovative method of treating osteoarthritis using multipotent mesenchymal bone marrow and placenta stem cells. This technique is already being tested in a clinical trial under the auspices of the Coordination Center for Organ, Tissue and Cell Transplantation of the Ministry of Health of Ukraine, and is also included in the official international registry (https://clinicaltrials.gov/ct2/results?cond=&term=NCT04453111&cntry=&state=&city=&dist=). One of the patients of the Institute of Cell Therapy, who has already experienced the effectiveness of cell therapy for knee joints osteoarthritis is the world-famous football player and coach of the national football team Andriy Shevchenko.

Sources: bioinformant.com, https://csict.com.ua/rnd-research-articles/оцінка-ефективності-застосування-ст-2/?lang=uk, https://clinicaltrials.gov/ct2/results?cond=&term=NCT04453111&cntry=&state=&city=&dist=